Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$616.98M$616.98Mderived+1.2% vs Q4 2022 Net Income-$98.65M-$98.65MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$189,827,000−11.9% Operating Incomederived$14,193,000−60.6% Operating Cash Flowderived$135,823,000N/M Free Cash Flowderived$125,958,000N/M Margins · derivedGross margin30.8%−4.6 pt vs Q4 2022
Operating margin2.3%−3.6 pt vs Q4 2022
Net margin-16.0%−14.0 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 14, 2024 · 74 d after period end